• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovo Nordisk

Novo Nordisk

Page 4 of 9
Tesla CEO Elon Musk attends the 10th Annual Breakthrough Prize Ceremony at Academy Museum of Motion Pictures.
Health
Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic
By Christiaan HetznerSeptember 25, 2024
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company's headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023.
Health
Novo Nordisk CEO takes aim at U.S. healthcare as he defends Ozempic pricing to Bernie Sanders
By Ryan HoggSeptember 24, 2024
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
Finance
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
By Sara Sjolin, Sanne Wass, Oliver Crook and BloombergSeptember 23, 2024
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Health
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
By Naomi Kresge and BloombergSeptember 12, 2024
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
Health
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
By Chris MorrisSeptember 11, 2024
Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict
Tech
Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict
By Sanne Wass and BloombergSeptember 3, 2024
A photo of the packet for anti-obesity drug Wegovy.
Health
Wegovy reduced Covid deaths in obese patients, study finds
By Madison Muller and BloombergAugust 30, 2024
A person sifts through a rack of clothing.
Retail
Secondhand luxury fashion thrives as Ozempic users purge their closets
By Sasha RogelbergAugust 29, 2024
Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy
Finance
Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy
By Sanne Wass and BloombergAugust 20, 2024
Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML
Finance
Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML
By Kari Lundgren and BloombergAugust 14, 2024
Here’s the real reason Ozempic-like weight-loss drugs are so popular
Commentary
Here’s the real reason Ozempic-like weight-loss drugs are so popular
By Bill NovelliAugust 12, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health
How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices
By Arthur Allen and KFF Health NewsAugust 7, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S's obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty Images
Retail
Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow
By AFPAugust 7, 2024
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
Newsletters
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By Lydia BelangerAugust 5, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary
I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By Angela FitchJuly 30, 2024
1
  • 2
  • 3
  • 4
  • 5
  • 6
...9
Most Popular
Success
Mark Cuban says he has the solution to growing income inequality, and it's to reward every employee—from CEO to janitor—with company stockplaceholder alt text
By Sasha RogelbergJuly 20, 2026
Success
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billionplaceholder alt text
By Sydney LakeJuly 20, 2026
AI
'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimisticplaceholder alt text
By Jason MaJuly 18, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.